Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7242743 | 0.92 | TSHR (0.54) | HSD17B10TSHRMAPTCAPN1CTSS | |
| SCHEMBL7234748 | 0.91 | MEN1 (0.48) | HSD17B10TSHRKMT2ACAPN1CTSS | |
| SCHEMBL7242371 | 0.88 | GPR6 (0.48) | HSD17B10TSHRMAPTKMT2ACAPN1 | |
| SCHEMBL7235181 | 0.84 | CAPN1 (0.50) | L3MBTL1HSD17B10SIGMAR1MAPTKMT2A | |
| SCHEMBL7238934 | 0.84 | L3MBTL1 (0.50) | L3MBTL1HSD17B10TSHRSIGMAR1MAPT | |
| SCHEMBL7238926 | 0.84 | CAPN1 (0.49) | L3MBTL1HSD17B10SIGMAR1MAPTKMT2A | |
| SCHEMBL7241206 | 0.83 | CHIA (0.59) | HSD17B10TSHRMAPTKMT2ACAPN1 | |
| SCHEMBL7234715 | 0.83 | TSHR (0.49) | HSD17B10TSHRSIGMAR1KMT2ACAPN1 | |
| SCHEMBL7232790 | 0.83 | TSHR (0.46) | HSD17B10TSHRMAPTCAPN1CTSS | |
| SCHEMBL7239763 | 0.82 | HSD17B10 (0.56) | HSD17B10TSHRMAPTKMT2ACAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562827-B1 | For the treatment of diseases in which increased calpain activity occurs such as neurodegenerative diseases or neuronal damage are caused by ischemia, trauma or mass hemorrhages | ABBOTT LABORATORIES | 2003-05-13 | — | — | US | disclosed |